National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
米国
引用
ジャーナル: Adv Sci (Weinh) / 年: 2024 タイトル: Ultrapotent Broadly Neutralizing Human-llama Bispecific Antibodies against HIV-1. 著者: Jianliang Xu / Tongqing Zhou / Krisha McKee / Baoshan Zhang / Cuiping Liu / Alexandra F Nazzari / Amarendra Pegu / Chen-Hsiang Shen / Jordan E Becker / Michael F Bender / Payton Chan / Anita ...著者: Jianliang Xu / Tongqing Zhou / Krisha McKee / Baoshan Zhang / Cuiping Liu / Alexandra F Nazzari / Amarendra Pegu / Chen-Hsiang Shen / Jordan E Becker / Michael F Bender / Payton Chan / Anita Changela / Ridhi Chaudhary / Xuejun Chen / Tal Einav / Young Do Kwon / Bob C Lin / Mark K Louder / Jonah S Merriam / Nicholas C Morano / Sijy O'Dell / Adam S Olia / Reda Rawi / Ryan S Roark / Tyler Stephens / I-Ting Teng / Emily Tourtellott-Fogt / Shuishu Wang / Eun Sung Yang / Lawrence Shapiro / Yaroslav Tsybovsky / Nicole A Doria-Rose / Rafael Casellas / Peter D Kwong / 要旨: Broadly neutralizing antibodies are proposed as therapeutic and prophylactic agents against HIV-1, but their potency and breadth are less than optimal. This study describes the immunization of a ...Broadly neutralizing antibodies are proposed as therapeutic and prophylactic agents against HIV-1, but their potency and breadth are less than optimal. This study describes the immunization of a llama with the prefusion-stabilized HIV-1 envelope (Env) trimer, BG505 DS-SOSIP, and the identification and improvement of potent neutralizing nanobodies recognizing the CD4-binding site (CD4bs) of vulnerability. Two of the vaccine-elicited CD4bs-targeting nanobodies, G36 and R27, when engineered into a triple tandem format with llama IgG2a-hinge region and human IgG1-constant region (G36×3-IgG2a and R27×3-IgG2a), neutralized 96% of a multiclade 208-strain panel at geometric mean ICs of 0.314 and 0.033 µg mL, respectively. Cryo-EM structures of these nanobodies in complex with Env trimer revealed the two nanobodies to neutralize HIV-1 by mimicking the recognition of the CD4 receptor. To enhance their neutralizing potency and breadth, nanobodies are linked to the light chain of the V2-apex-targeting broadly neutralizing antibody, CAP256V2LS. The resultant human-llama bispecific antibody CAP256L-R27×3LS exhibited ultrapotent neutralization and breadth exceeding other published HIV-1 broadly neutralizing antibodies, with pharmacokinetics determined in FcRn-Fc mice similar to the parent CAP256V2LS. Vaccine-elicited llama nanobodies, when combined with V2-apex broadly neutralizing antibodies, may therefore be able to fulfill anti-HIV-1 therapeutic and prophylactic clinical goals.